Policymakers Must Sustain American Life Sciences Leadership
- Feb 20
- 1 min read
By: Dan Leonard, Executive Director, We Work For Health
Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives.
Last year marked a transformative moment for the biopharmaceutical sector: the industry committed to nearly $500 billion in domestic investments, an almost 1,500% surge compared to 2024.
My organization, We Work For Health, documents where these investments flow on our U.S. Biopharma Investment Watch. It shows that from coast to coast, companies announced or broke ground last year on dozens of next-generation research facilities, expanded their stateside manufacturing capacity and laid the foundation for accelerating medical breakthroughs. This unprecedented deployment of capital signals industry confidence in America’s capacity to lead the next era of medical discovery.